Creating a private label custom sunscreen starts with the sales market, SPF target, UVA performance, water-resistance claim, formula type, package, and manufacturing volume. In the U.S., sunscreen is an OTC drug; FDA rules cover permitted active ingredients, SPF testing, Broad Spectrum testing, Drug Facts labeling, and 40- or 80-minute water-resistance claims. In the EU, sunscreen is regulated as a cosmetic, while UVA protection should reach at least one-third of the labeled SPF. A practical development program normally includes formula screening, efficacy testing, stability work, packaging compatibility, regulatory review, pilot production, and finished-product quality specifications before full-scale filling.
The first specification should describe where the product will be sold rather than simply requesting “SPF 50.” A U.S. facial sunscreen, an EU beach lotion, and a product intended for several regions may need different UV-filter systems, label wording, testing records, and manufacturing documentation. FDA’s current OTC Monograph M020 lists permitted sunscreen actives and their concentration limits; zinc oxide and titanium dioxide are listed up to 25%, while other listed actives have their own maximum concentrations.
A manufacturer therefore needs a written brief covering target country, SPF, Broad Spectrum or UVA requirement, water resistance, texture, fragrance, tint, pack size, target cost, first production quantity, and annual forecast. A 50 mL facial fluid selling through specialty retail has a different material budget from a 150 mL family lotion intended for mass retail, even when both carry SPF 50.
A useful brief might read: “U.S. daily facial sunscreen, SPF 50, Broad Spectrum, fragrance-free, lightweight lotion, low shine, minimal visible residue, 50 mL airless pump, 5,000-unit first order, no water-resistance claim.”
Once the commercial specification is fixed, the brand can choose between an existing private-label base, a modified platform, or a new formula. An established base usually reduces development work because its processing method and earlier performance data are already known; changing oils, powders, pigments, fragrance, emulsifiers, or film formers can still change SPF performance and may require additional testing.
A new formula gives more control over skin feel, finish, tint, UV-filter combination, and supporting skincare ingredients, but each additional variable adds evaluation work. Mineral products containing zinc oxide or titanium dioxide often require careful particle dispersion because uneven distribution can increase whitening, viscosity, settling, or drag. FDA documentation currently permits zinc oxide and titanium dioxide up to 25% under M020, while its 2021 proposed order also discussed GRASE status for both at concentrations up to 25%.
The U.S. filter landscape also changed in 2026. On June 9, 2026, FDA announced the addition of bemotrizinol to the permitted sunscreen active-ingredient list, the first new sunscreen active added to the U.S. OTC framework in roughly 20 years. A manufacturer serving the American market should therefore provide its current regulatory basis rather than relying on an ingredient list prepared several years earlier.
Formula selection then moves from ingredient legality to measured protection. SPF mainly describes protection against erythema-producing UV radiation, so an SPF number alone does not describe the entire UVA profile. EU Recommendation 2006/647/EC states that UVA protection should equal at least one-third of the labeled SPF and recommends a wavelength endpoint of at least 370 nm for broad protection.
| Development item | Example specification | What should be verified |
|---|---|---|
| SPF | 30 or 50 | Finished-formula test result |
| UVA | Broad Spectrum / EU UVA target | Applicable regional method |
| Water resistance | None, 40 min, or 80 min | Claim-specific test |
| Pack size | 40–150 mL | Fill tolerance and dispensing |
| Initial volume | 3,000–10,000 units | Formula and packaging MOQ |
| Shelf-life program | Often 24–36 months as a commercial target | Supported by the manufacturer’s stability program |
For the U.S. Broad Spectrum method, FDA specifies UV measurements between 290 and 400 nm. The test uses sunscreen applied to roughened PMMA plates at 0.75 mg/cm², with at least five mean-transmittance measurements made on three different plates. The method also specifies an 800 J/m²-effective pre-irradiation dose. Those numbers show why Broad Spectrum status cannot be assigned simply from the ingredient percentages shown on a formulation sheet.
Wearability deserves the same attention because consumers apply sunscreen repeatedly and over relatively large skin areas. During sample review, compare spread time, tack after 5–10 minutes, shine, residue, pilling over moisturizer, movement around the eyes, transfer onto clothing, and reapplication over the first layer. Facial formulas can also be checked under foundation after 15 minutes to see whether film formation causes rolling or uneven makeup.
Supporting skincare ingredients should be selected only after the sunscreen base performs properly. Niacinamide, panthenol, vitamin E, glycerin, ceramides, and hyaluronic acid may fit facial positioning, but changing the water phase, solvent balance, powder level, or emollient phase can alter viscosity and the way the UV filters form a film. A brand already selling products such as niacinamide eye cream may want a related skincare story, but the sunscreen still needs performance testing as a finished formula.
Water resistance adds another measurable requirement. FDA permits labeling for “Water Resistant (40 minutes)” or “Water Resistant (80 minutes)” when the relevant procedure is passed; terms such as “waterproof” are not permitted because sunscreen eventually washes from the skin. FDA’s 40-minute procedure includes two 20-minute water immersions separated by 15-minute drying periods, while the 80-minute claim uses four immersion-and-drying sequences.
A sports product should not be described as water resistant merely because it contains a film-forming polymer. The stated 40- or 80-minute performance must match the applicable finished-product test.
With performance targets established, stability and packaging work can start on the approved formula. A typical manufacturer may place samples under room-temperature, elevated-temperature, refrigerated, and freeze-thaw conditions while checking appearance, odor, pH, viscosity, phase separation, color, and package interaction at scheduled intervals. A 24- or 36-month commercial shelf-life claim should be supported by an appropriate stability program rather than copied from another product.
Packaging compatibility needs the actual sunscreen bulk because high oil content, organic filters, mineral particles, solvents, or film formers can behave differently with plastics, seals, pumps, and printing. A 50 mL airless pack may work with a light emulsion but fail to prime with a high-viscosity mineral formula; a tube may show panel distortion, cap leakage, decoration lifting, or product drying around the opening after extended storage.
Packaging MOQ should also be separated from formula MOQ. A factory may be able to fill 3,000 units while a custom-colored tube supplier requires 10,000 pieces. Brands should request pricing at several quantities—such as 3,000, 5,000, 10,000, and 25,000 units—because decoration, carton printing, pumps, and specialized raw materials may produce larger cost changes than the sunscreen bulk itself.
Regulatory artwork follows formula and pack selection. U.S. sunscreen labels use OTC drug labeling requirements, including Drug Facts, active ingredients, uses, warnings, directions, SPF presentation, and applicable water-resistance language. FDA directions specify application 15 minutes before sun exposure and, for products without water-resistance qualification, reapplication at least every 2 hours; qualifying water-resistant products require additional reapplication instructions after 40 or 80 minutes of swimming or sweating.
Claims outside SPF and water resistance need separate review. “Non-comedogenic,” “dermatologist tested,” “sensitive skin,” “no white cast,” “24-hour hydration,” or similar statements may require finished-product support appropriate to the claim and sales region. Ingredient supplier literature can describe a raw material, but it does not automatically substantiate the same statement for a complete sunscreen containing 20 or more ingredients.
Production scale adds another source of variation. A 1 kg laboratory batch and a 300 kg manufacturing batch may use different shear rates, heating times, cooling rates, powder-addition speeds, vacuum conditions, and homogenization periods. For mineral sunscreen in particular, insufficient scale-up control can change particle distribution and final viscosity, so a pilot batch can be used to establish manufacturing parameters before a large packaging run.
Finished-product specifications turn sample approval into measurable acceptance limits. The file may include appearance, odor, pH range, viscosity range, specific gravity, microbiological limits, fill weight, dispensing performance, package appearance, batch coding, and applicable active-ingredient requirements. Production samples from each lot can then be compared with the approved standard rather than judged by appearance alone.
A supplier review should cover the same level of detail. For a U.S. OTC sunscreen project in 2026, ask how the facility handles OTC manufacturing requirements, batch traceability, raw-material qualification, deviations, change control, complaints, retain samples, finished-product release, and test documentation. The brand should also confirm whether the company offering the product actually manufactures it or uses another facility for compounding and filling.
Commercial cost should be calculated beyond the quoted unit price. A $3.00 ex-factory product can require separate spending on SPF/UVA work, compatibility testing, cartons, labels, freight, import duty, warehousing, inspection, and fulfillment preparation. When 5,000 units share a $10,000 package of development and testing expenses, that expense alone adds $2.00 per unit before freight or retailer margin is considered.
Formula ownership needs written terms before paying development fees. The agreement should state whether the manufacturer owns the base, whether another brand may purchase the same composition, whether requested modifications are exclusive, who owns testing reports, and whether exclusivity depends on an annual volume such as 50,000 units. “Custom” in a sales quotation does not necessarily transfer intellectual-property ownership.
Ordering sequence also affects waste. Printed packaging should normally follow formula approval, initial performance work, ingredient review, and compatibility assessment because a late change in active ingredients, viscosity, directions, INCI listing, or claims can make 10,000 already-printed tubes unusable. Artwork, master samples, bulk specifications, packaging drawings, fill quantity, batch-code format, and shipping-case information should all carry controlled approval versions before filling begins.
During commercial manufacture, records should connect every batch with its raw materials, processing parameters, in-process checks, fill records, microbiological release, packaging lot numbers, and retained samples. A brand ordering 10,000 units can also define an inspection plan covering fill quantity, leakage, printing, carton condition, coding, and functional dispensing before shipment, giving both parties measurable acceptance criteria rather than relying on visual approval.